Newsletter · · Ashutosh Agarwal

Medicare Opens Obesity Drug Coverage as the GLP-1 Bridge Goes Live - Weekly Pharma, Biotech and Life Sciences Podcast Recap - Week of July 5, 2026

Weekly pharma, biotech and life-sciences podcast recap for the week of July 5, 2026. Medicare's first-ever obesity-drug coverage went live July 1 through an 18-month GLP-1 Bridge pilot, alongside a biotech M&A wave, GLP-1 pricing pressure and a broad healthcare re-rating.

Weekly Pharma, Biotech & Life Sciences Podcast Recap

Week of July 5, 2026: Medicare Opens Obesity Drug Coverage as the GLP-1 Bridge Goes Live

A survey of pharma, biotech and life-sciences podcast episodes published in the trailing seven days, dedicated sector shows plus healthcare segments from generalist investor programs. Coverage this week was strong (roughly 30+ investment-relevant episodes). The single biggest catalyst was Medicare's first-ever obesity-drug coverage, which went live July 1.

1. Dominant Themes

1) Medicare opens obesity-drug coverage: the week's defining event. Starting July 1, 2026, eligible Medicare seniors can access GLP-1 obesity drugs from Lilly and Novo Nordisk for the first time, through an 18-month pilot dubbed the "Bridge" program (July 2026 – December 2027). Beneficiaries pay a $50 monthly copay; drug makers charge a negotiated $245/month, with taxpayers covering roughly $195/month. Federal law had long banned Medicare obesity-drug coverage; CMS initially proposed a permanent program but implemented a temporary pilot after industry pushback over cost, and continuation past end-2027 is unclear. Leerink/Leeroy Partners analyst David Reisinger expects Medicare obesity coverage to eventually generate ~$1 billion in annual revenue for each of Lilly and Novo. Lilly hit an all-time high of $1,238 on June 29. Squawk on the Street; Reuters World News; Weight and Healthcare; Off the Chart: A Business of Medicine Podcast

2) GLP-1 market maturation, pricing pressure and the pivot to pills. On Running Through Walls, Venrock's Bob Kocher predicted the GLP-1 market will consolidate like the erectile-dysfunction and statin markets, generic competition arriving soon, rebates above 60%, and margin compression on both branded and generic tiers, though adoption stays broad because the drugs work and will get cheap enough for payers. The GLP-1 "economy" is now mainstream: The Important Part: Investing with Liz Thomas cited 1 in 8 Americans currently on the drugs, projected 10–12% compound growth for the next decade, Lilly and Novo holding ~80% share, and pricing pressure building from compounding pharmacies (Empire in Texas, Red Rock in Utah) and telehealth (Hims, Hers, Ro), with AstraZeneca and Pfizer entering. The competitive battle is shifting to oral formulations, Novo's research says 75% of Medicare seniors would prefer pills to injections, with Novo's Wegovy pill and Lilly's oral launched earlier this year.

3) Biotech M&A wave and a sector re-rating. AbbVie agreed to acquire Apogee Therapeutics for roughly $11 billion in debt financing (lead asset zumilokibat for atopic dermatitis); Sangamo Therapeutics filed for Chapter 11, selling assets to Eli Lilly ($50M) and Astellas ($25M + $25M milestones). Citeline Podcasts, Scrip's Five Must-Know Things. Healthcare rose nearly 7% in June, its best month since November 2025, and BofA strategist Jill Carey Hall called biotech the "highest quality in 12 years." Closing Bell; Bloomberg Surveillance; Power Lunch

4) FDA reform and drug-pricing policy. BioCentury flagged FDA clinical-trial reforms (BioCentury This Week). The FDA launched a "PreCheck" pilot to pre-clear roughly 10 third-party manufacturing sites and compress approval timelines (Telltales). On pricing: most-favored-nation (MFN) agreements with 17 big-pharma companies require US Medicaid-covered drug prices in line with other developed markets; Dr. Oz touted affordability efforts and trumprx.gov (The Capitalism and Freedom in the Twenty-First Century Podcast); a Wyden/Schumer proposal would cap original-Medicare out-of-pocket costs at $5,000 (The Seven Figures Or Bust Podcast!).

5) AI in drug discovery. Recursion's CEO described using AI across chemistry, biology and trial design to attack the ~95% drug-discovery failure rate, citing $500M+ in partnerships with Sanofi and Roche and a lead program at proof of concept (Opto Sessions).

6) Manufacturing reshoring / CDMO capacity. Honeywell Process Automation's CEO argued there is a ~$2 billion annual revenue loss from manufacturing capacity constraints delaying drug launches, with ~$300 billion of US pharma onshoring expected over the next five years driven by geopolitics (Off Script: A Pharma Manufacturing Podcast).

7) Patent cliffs. Roughly $230 billion of US (and nearly $300 billion of global) prescription revenue faces patent expiration through 2032, with some companies risking 30%+ revenue loss in compressed windows (AI For Pharma Growth); a patent-strategy episode framed the GLP-1 cliff as the Hatch-Waxman bargain working as intended (Patently Strategic).

8) China / outbound-investment policy. At the BIO conference, business-development executives from J&J, Sanofi and CSL cautioned against US efforts to block US–China dealmaking under the proposed BINSA/COINS Act amendment; Sanofi said a potential China deal already fell through partly on these concerns (Citeline Podcasts, Scrip's Five Must-Know Things).

9) Oncology pipeline (ASCO 2026). A heavy volume of clinical/CME episodes recapped ASCO 2026 breast, lung, AML and myeloma readouts, largely academic in framing but naming sponsor companies (e.g., Pfizer/Celcuity's gedatolisib in VIKTORIA-1; Daiichi Sankyo/AstraZeneca's T-DXd across breast and lung). Oncology Brothers, ASCO 2026 Breast Highlights; ASCO Daily News

2. Active Debates

Lilly vs Novo on obesity: value trap or beaten-down opportunity? On Wall Street Wildlife, a Novo shareholder laid out both sides: Lilly leads the market roughly 60–40; Novo's Cagrisema lost a February head-to-head trial, the stock fell ~15% in a day and shed ~$100 billion in market cap, and it is down ~45% over the past year. Bull case: Novo trades at ~10x earnings vs Lilly's ~40x, pays a dividend, is running ~$2.3 billion of buybacks and cut ~9,000 jobs (~11% of its workforce) to improve efficiency. Bear case: it is a structural #2, "always going to play second place," and the chart is a steep downtrend, a possible value trap.

Oral vs injectable GLP-1. With 75% of seniors preferring pills, the next competitive front is oral drugs (Novo's Wegovy pill, Lilly's oral) rather than injectables (Squawk on the Street).

Is the GLP-1 duopoly durable, or commoditizing? Kocher's consolidation/margin-compression thesis (Running Through Walls) sits against the "still early, massive untapped market" view (The Important Part).

Healthcare: undervalued rotation candidate? State Street's Daniel Santiago called healthcare "the most intriguing sector", beaten down on GLP-1 adoption fears but now undervalued, offering defensiveness and idiosyncratic growth, though it will keep struggling as long as capital stays concentrated in AI mega-caps (Lead-Lag Live). Closing Bell noted biotech is building a "massive base pattern" and is a constructive buy-on-pullbacks area, but "won't rescue the broad market" into expected summer volatility (Closing Bell).

Have biotech valuations bottomed? BofA's Jill Carey Hall: small-cap healthcare/biotech had been unattractive but is "finally starting to look attractive," with biotech at its highest quality in 12 years as more names turn profitable and large pharma hunts small-cap targets, though small- and mid-caps now trade at similar valuations (Bloomberg Surveillance).

AI drug discovery: real or hype? Recursion's milestone-and-partnership tally is the bull case this week (Opto Sessions). A crypto-turned-macro investor separately called biotech a major AI beneficiary, citing XBI strength (The Pomp Podcast).

China threat: block deals or keep them? Big-pharma BD leaders argued restricting US–China deals would harm patients and is already chilling transactions (Citeline Podcasts).

3. Stock-by-Stock Bull / Bear

  • Eli Lilly (LLY), Bull: "goes from strength to strength," a step ahead of Novo on both weight-loss drugs and pipeline, plus a non-obvious lever in fighting back on the 340B program; all-time high $1,238 (6/29) and a ~$1B Medicare obesity opportunity. Bear: rich at ~40x earnings. Telltales; Squawk on the Street; Wall Street Wildlife

  • Novo Nordisk (NVO), Bull: ~10x earnings, cheap for a top-tier pharma, dividend-payer, ~$2.3B buybacks. Bear: perennial #2, Cagrisema trial failure, down ~45% on the year, possible value trap. Wall Street Wildlife

  • Pfizer (PFE), Bull: "so incredibly cheap"; prostate-cancer imaging sales stabilized; Alzheimer's imaging-agent FDA decisions due later this year; ~7% dividend as a defensive play. Bear: patent cliffs. Telltales; CNBC's "Fast Money"

  • AbbVie (ABBV), Acquiring Apogee Therapeutics for ~$11B (debt). Lead asset zumilokibat (atopic dermatitis) is a potential "mega-blockbuster" with ~four-times-a-year dosing after induction; CEO Robert Michael framed it as strengthening AbbVie's highest-earning immunology segment into the 2030s. Would compete with Sanofi/Regeneron's Dupixent and Lilly's Ebglyss; possible US approval in 2030. Citeline Podcasts

  • Sangamo Therapeutics (SGMO), Filing Chapter 11; assets sold to Lilly ($50M) and Astellas ($25M + $25M milestones); reported a $31M Q1 net loss and ended Q1 with $27.6M cash; already delisted from NASDAQ to OTC. Deals subject to higher bids at auction. Citeline Podcasts

  • BioNTech (BNTX), Bear-leaning: "slow to get any revenue going," still sitting on cash. Telltales

  • Moderna (MRNA), Bear-leaning: has "run through most of the cash" earned from COVID vaccines; deep pipeline but heavy spend. Telltales

  • Vertex (VRTX), Mixed: non-opioid painkiller "slow out of the mark" with a flatter-than-hoped adoption S-curve as it works through payer reimbursement, though sales have been "ticking up" the last two months. Telltales

  • Lantheus (LNTH), FDA rejection on a diagnostic tied to third-party manufacturing controls (not efficacy); expected to resubmit once controls are fixed. Telltales

  • Kura Oncology (KURA), Bull: menin inhibitor ziftomenib seen reaching ~$3 billion peak US sales if approved in frontline AML (treating 50–60% of patients), with Phase 3 EHA data showing patients disease-free at 2+ years; also advancing next-gen farnesyl-transferase inhibitor darolafarnib combined with Revolution Medicines' RAS inhibitor for pancreatic cancer. The Long Run with Luke Timmerman

  • Recursion Pharmaceuticals (RXRX), AI drug-discovery platform; $500M+ Sanofi/Roche partnerships, a dozen+ development-candidate milestones, one program at proof of concept. Opto Sessions

  • Summit Therapeutics (SMMT) / Akeso, Evaluate ranks the dual PD-1/VEGF bispecific ivonescimab as the most valuable R&D project by NPV: >$25B NPV, projected 2032 sales of $8.5B. Citeline Podcasts

  • AstraZeneca (AZN), Obesity pipeline includes oral small-molecule GLP-1 (alecoglipron), GLP-1/glucagon and GLP-1/GIP dual agonists, and an activin inhibitor (AZD-1043) expected to deliver ~10% weight loss as monotherapy for elderly/frail patients, though AZ "lacks the depth" of Lilly. BioCentury This Week

  • Hims & Hers (HIMS), Board member David Wells disclosed buying $1.2M of stock; ongoing Novo partnership and GLP-1 telehealth exposure. Hims House

  • Harrow (HROW), Product-liability jury trial set for December 7, 2026, tied to a legacy compounded product; hosts see no current sign it is a bellwether case but flag downside if a plaintiff wins. Telltales

  • PharmAla Biotech (CSE: MDMA / OTCQB: MDXXF), Announced an SPV to form Restora Neuroscience (preclinical APA01, 50-50 equity, 3% royalty) and a term sheet licensing ALA002 to Jupiter Neurosciences valued at over $100 million ($3.33M upfront plus milestones). WTR Small-Cap Spotlight

  • Managed care, A 2.5% Medicare Advantage rate increase for 2027 is a tailwind; managed care performed well alongside pharma in June. Closing Bell

4. Notable Quotes

  • On the GLP-1 endgame, Bob Kocher (Venrock): the market will consolidate "like the erectile dysfunction and statin markets," with generic competition arriving soon, rebates above 60%, and margin compression on both branded and generic tiers, but broad adoption because the drugs are effective and will "become cheap enough for payer coverage." Running Through Walls

  • On Pfizer, "I've got updated the Pfizer page. And Pfizer is so incredibly cheap. I guess it's just patent cliffs." Telltales

  • On BioNTech and Moderna, "BioNTech just seems slow to get any revenue going… BioNTech's still sitting on their cash. Moderna's getting to the point where they've run through most of the cash they've made from doing COVID vaccines." Telltales

  • On Novo Nordisk, "the bull and the bear case are kind of the same thing… you're buying a beaten down cheap company today [that] is always going to play second place to Eli Lilly… but maybe that is reflected in the valuation because it's essentially a quarter of the valuation of Eli Lilly on a price-to-earnings basis." Wall Street Wildlife

  • On the Medicare obesity opportunity, analyst David Reisinger "expects Medicare coverage of obesity drugs to eventually rake in $1 billion in annual revenue for both Lilly and Novo," while 75% of Medicare seniors "would actually prefer to take pills over injections." Squawk on the Street

  • On AbbVie/Apogee, CEO Robert Michael said acquiring Apogee will bring in "multiple differentiated pipeline candidates that should provide mega-blockbuster revenue," describing zumilokibat as a "pipeline-in-a-product" asset. Citeline Podcasts

5. Catalysts to Watch

  • Medicare GLP-1 "Bridge" program live July 1, 2026; expires end-2027, watch for the government's plan to extend or replace coverage. Squawk on the Street

  • Pfizer Alzheimer's imaging-agent FDA decisions expected later this year. Telltales

  • Lantheus resubmission of its rejected diagnostic once third-party manufacturing controls are remediated. Telltales

  • AbbVie / Apogee zumilokibat Phase 3 slated to start later this year; potential US approval in 2030. Citeline Podcasts

  • Sangamo Chapter 11 asset auction, Lilly and Astellas are stalking-horse bidders; higher bids possible. Citeline Podcasts

  • Kura Oncology ziftomenib frontline AML program (Phase 3). The Long Run with Luke Timmerman

  • BINSA / COINS Act amendment on US–China biopharma investment screening, legislative progress to monitor. Citeline Podcasts

  • Harrow product-liability jury trial, December 7, 2026. Telltales

  • FDA "PreCheck" manufacturing pre-clearance pilot, a structural timeline-compression story for approvals. Telltales